PMC:7650537 / 27977-28553 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T166","span":{"begin":133,"end":136},"obj":"Body_part"},{"id":"T167","span":{"begin":143,"end":151},"obj":"Body_part"},{"id":"T168","span":{"begin":459,"end":462},"obj":"Body_part"}],"attributes":[{"id":"A166","pred":"fma_id","subj":"T166","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A167","pred":"fma_id","subj":"T167","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A168","pred":"fma_id","subj":"T168","obj":"http://purl.org/sig/ont/fma/fma62872"}],"text":"The following are available online at https://www.mdpi.com/2076-2607/8/10/1572/s1. Table S1: Characteristics of the eight SARS-CoV-2 IgG/total antibody tests. Figure S1: Raw data from the plaque reduction neutralization test used as reference # 2 in the validation part of this study. Figure S2: Raw data from the plaque reduction neutralization test to investigate the kinetics of the virus-neutralizing antibodies. Figure S3: Development of high SARS-CoV-2 IgG avidities in three SARS-CoV-2 patients. Figure S4: Agreement of titers from two independent neutralization tests."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T137","span":{"begin":122,"end":130},"obj":"Disease"},{"id":"T138","span":{"begin":448,"end":456},"obj":"Disease"},{"id":"T139","span":{"begin":482,"end":490},"obj":"Disease"}],"attributes":[{"id":"A137","pred":"mondo_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A138","pred":"mondo_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A139","pred":"mondo_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The following are available online at https://www.mdpi.com/2076-2607/8/10/1572/s1. Table S1: Characteristics of the eight SARS-CoV-2 IgG/total antibody tests. Figure S1: Raw data from the plaque reduction neutralization test used as reference # 2 in the validation part of this study. Figure S2: Raw data from the plaque reduction neutralization test to investigate the kinetics of the virus-neutralizing antibodies. Figure S3: Development of high SARS-CoV-2 IgG avidities in three SARS-CoV-2 patients. Figure S4: Agreement of titers from two independent neutralization tests."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T216","span":{"begin":79,"end":81},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T217","span":{"begin":89,"end":91},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T218","span":{"begin":152,"end":157},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T219","span":{"begin":166,"end":168},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T220","span":{"begin":220,"end":224},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T221","span":{"begin":292,"end":294},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T222","span":{"begin":292,"end":294},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"},{"id":"T223","span":{"begin":346,"end":350},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T224","span":{"begin":386,"end":391},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T225","span":{"begin":570,"end":575},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"The following are available online at https://www.mdpi.com/2076-2607/8/10/1572/s1. Table S1: Characteristics of the eight SARS-CoV-2 IgG/total antibody tests. Figure S1: Raw data from the plaque reduction neutralization test used as reference # 2 in the validation part of this study. Figure S2: Raw data from the plaque reduction neutralization test to investigate the kinetics of the virus-neutralizing antibodies. Figure S3: Development of high SARS-CoV-2 IgG avidities in three SARS-CoV-2 patients. Figure S4: Agreement of titers from two independent neutralization tests."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T89","span":{"begin":292,"end":294},"obj":"Chemical"},{"id":"T90","span":{"begin":424,"end":426},"obj":"Chemical"},{"id":"T91","span":{"begin":510,"end":512},"obj":"Chemical"}],"attributes":[{"id":"A89","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"},{"id":"A90","pred":"chebi_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/CHEBI_29388"},{"id":"A91","pred":"chebi_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/CHEBI_29401"}],"text":"The following are available online at https://www.mdpi.com/2076-2607/8/10/1572/s1. Table S1: Characteristics of the eight SARS-CoV-2 IgG/total antibody tests. Figure S1: Raw data from the plaque reduction neutralization test used as reference # 2 in the validation part of this study. Figure S2: Raw data from the plaque reduction neutralization test to investigate the kinetics of the virus-neutralizing antibodies. Figure S3: Development of high SARS-CoV-2 IgG avidities in three SARS-CoV-2 patients. Figure S4: Agreement of titers from two independent neutralization tests."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T17","span":{"begin":424,"end":439},"obj":"http://purl.obolibrary.org/obo/GO_0072020"}],"text":"The following are available online at https://www.mdpi.com/2076-2607/8/10/1572/s1. Table S1: Characteristics of the eight SARS-CoV-2 IgG/total antibody tests. Figure S1: Raw data from the plaque reduction neutralization test used as reference # 2 in the validation part of this study. Figure S2: Raw data from the plaque reduction neutralization test to investigate the kinetics of the virus-neutralizing antibodies. Figure S3: Development of high SARS-CoV-2 IgG avidities in three SARS-CoV-2 patients. Figure S4: Agreement of titers from two independent neutralization tests."}

{"project":"LitCovid-sentences","denotations":[{"id":"T217","span":{"begin":0,"end":82},"obj":"Sentence"},{"id":"T218","span":{"begin":83,"end":92},"obj":"Sentence"},{"id":"T219","span":{"begin":93,"end":158},"obj":"Sentence"},{"id":"T220","span":{"begin":159,"end":169},"obj":"Sentence"},{"id":"T221","span":{"begin":170,"end":284},"obj":"Sentence"},{"id":"T222","span":{"begin":285,"end":295},"obj":"Sentence"},{"id":"T223","span":{"begin":296,"end":416},"obj":"Sentence"},{"id":"T224","span":{"begin":417,"end":427},"obj":"Sentence"},{"id":"T225","span":{"begin":428,"end":502},"obj":"Sentence"},{"id":"T226","span":{"begin":503,"end":513},"obj":"Sentence"},{"id":"T227","span":{"begin":514,"end":576},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The following are available online at https://www.mdpi.com/2076-2607/8/10/1572/s1. Table S1: Characteristics of the eight SARS-CoV-2 IgG/total antibody tests. Figure S1: Raw data from the plaque reduction neutralization test used as reference # 2 in the validation part of this study. Figure S2: Raw data from the plaque reduction neutralization test to investigate the kinetics of the virus-neutralizing antibodies. Figure S3: Development of high SARS-CoV-2 IgG avidities in three SARS-CoV-2 patients. Figure S4: Agreement of titers from two independent neutralization tests."}

{"project":"LitCovid-PubTator","denotations":[{"id":"484","span":{"begin":482,"end":492},"obj":"Species"},{"id":"485","span":{"begin":493,"end":501},"obj":"Species"},{"id":"486","span":{"begin":122,"end":132},"obj":"Species"},{"id":"487","span":{"begin":448,"end":458},"obj":"Species"}],"attributes":[{"id":"A484","pred":"tao:has_database_id","subj":"484","obj":"Tax:2697049"},{"id":"A485","pred":"tao:has_database_id","subj":"485","obj":"Tax:9606"},{"id":"A486","pred":"tao:has_database_id","subj":"486","obj":"Tax:2697049"},{"id":"A487","pred":"tao:has_database_id","subj":"487","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The following are available online at https://www.mdpi.com/2076-2607/8/10/1572/s1. Table S1: Characteristics of the eight SARS-CoV-2 IgG/total antibody tests. Figure S1: Raw data from the plaque reduction neutralization test used as reference # 2 in the validation part of this study. Figure S2: Raw data from the plaque reduction neutralization test to investigate the kinetics of the virus-neutralizing antibodies. Figure S3: Development of high SARS-CoV-2 IgG avidities in three SARS-CoV-2 patients. Figure S4: Agreement of titers from two independent neutralization tests."}